Omnes Capital's investments

Sector 
Infrastructure
Entry Date 
2012
Business 
Renewable Energy

Solar Infrastructure

Solar farm portfolio
Sector 
Business services
Entry Date 
2012
Business 
Small-Cap Buyout & Growth Capital
Sales 
€9 million in 2014

Mirabeau

Building security specialist

Mirabeau is a group formed of two SMEs specialised in building security.
Comtra designs, manufactures and distributes natural smoke extraction and aeration products. Unitecnic designs, manufactures and distributes access control products, harnessing RFID technology in particular. Thanks to its multidisciplinary research office (mechanics, electronics and networking), the Mirabeau group possesses patents and innovative solutions at the cutting edge of its markets. Its customers are professional distributors, joiners, locksmiths, installation contractors and façade specialists. Comtra and Unitecnic work on a number of flagship construction projects (head offices, 
museums, hospitals, stadia, etc.).

 

Sector 
Independent power producer
Entry Date 
2012
Business 
Renewable Energy

Abakus Solar

A leading, international system company for photovoltaics
Abakus solar AG was founded in 1995 and is a leading, international system company for photovoltaics with comprehensive technical competence ranging from the small power plant to the megawatt solar park. The main business areas of the company are the planning and turnkey installation of photovoltaic power plants, wholesale trading with top-class components and complete photovoltaic systems, as well as the technical operational management of solar power plants.
Sector 
Medical devices
Entry Date 
2011
Business 
Venture Capital

Pixium

Up-and-coming leader in bionic vision and vision restoration systems (VRS)

Pixium Vision was founded in December 2011 by Bernard Gilly, Professor José-Alain Sahel, and several highly renowned scientists from prestigious academic and technology institutions. The company develops innovative vision restoration systems (VRS) that are active medical devices. They can be implanted to treat blindness caused by degeneration of the photo-receptor cells of the retina. VRS stimulate the retina to produce a bionic vision and aim to significantly improve the independence, mobility and quality of life of patients who have lost their sight. Called IRIS® (in clinical trials) and PRIMA (under development), these VRS harness the latest advances in microelectronics/nanoelectronics, optronics, neurobiology and software. With the help of these technologies, Pixium Vision ultimately aims to provide a therapeutic solution delivering bionic vision as close as possible to normal vision.

“Within ten years, we can become the world leader in the market.”
BERNARD
GILLY
Executive Chairman
of Pixium Vision
Pixium Vision

A long-term view

In June 2014, Omnes Capital supported the initial public offering made by Pixium Vision, a start-up specialising in vision restoration systems (VRSs). The IPO was highly successful, as one would expect for a company at the leading edge of research into visual impairment. A month later, Bernard Gilly, head of Pixium Vision, confirmed its success, with a total of €39.5 million ultimately raised.
BERNARD GILLY
Executive Chairman of Pixium Vision

Disruptive innovation

Alexia Perouse (Partner at Omnes Capital) and Bernard Gilly first discussed vision restoration systems in the early 2000s. "VRSs aim to enable blind people to perceive shapes and movements, a really tremendous project. But their design came up against two hurdles, systems miniaturisation and real-time image transmission", explains Bernard Gilly. 

 

Pixium overcame these hurdles in 2011 when it launched IRIS (short for Intelligent Retinal Implant System), consisting of a pair of glasses with an integrated mini-camera linked to a pocket computer and a retinal implant that stimulates the brain cells. 

 

"It met all our criteria for investment: disruptive technology, a seasoned management team and a promising medtech sector", says Alexia Perouse. So in 2012, Omnes Capital invested €5 million.

BERNARD
GILLY
Executive Chairman
of Pixium Vision
What sets Pixium apart from its competitors?
Our technology. We are pioneers in VRSs working as artificial retinas. IRIS, our first implant, has between 50 and 150 electrodes and can be implanted under general anaesthetic in two hours. PRIMA, the next generation, will have more than one thousand wireless electrodes and will be implanted under local anaesthetic in just 30 minutes. Both are being developed by an international network of research scientists from the Vision Institute, Université Pierre-et- Marie-Curie and the universities of Stanford and Jerusalem.
What do you expect from your partnership with Omnes Capital?
Omnes Capital has always been a partner that assesses our decisions, our strategy and our new hires, such as Pierre Kemula (former head of Investor Relations at Ipsen) who joined us as CFO last June. Alexia Perouse and her team know our project intimately, as they do the biotechnology and medical devices markets in general. We are united by strong mutual trust, which also stems from our long-standing relationship with Alexia, whom I have known since 2000.
What are your ambitions for the next few years?
The market is structuring itself. Within ten years, we can become a world leader with IRIS and PRIMA, but also with our R&D work on optical nerve pathologies, such as glaucoma. Will this growth be achieved alone or as part of a major group following a buyout? Only time will tell.

Timeline

• 2011: Bernard Gilly founds Pixium Vision with a group of scientists working at the Vision Institute and Université Pierre-et-Marie-Curie
• 2012: The first funding round organised with Omnes Capital raises €23.5 million
• 2013: Clinical trials begin on IRIS
• 2014: The IPO raises €39.5 million
• 2015: Development of IRIS begins in the United-States
pixium-vision
Sector 
SaaS / Cloud
Entry Date 
2011
Business 
Venture Capital

viavoo

Software suite in SaaS mode providing semantic analysis of interactions

A SaaS developer, viavoo can provide real-time analysis of consumer feedback to gain insight into their online or point-of-sale shopping experience, their views about products and services or about after-sales service, etc.
Operating across multiple channels (email, chat, satisfaction surveys, blogs, forums, opinions, social media), the linguistic technology developed by viavoo provides results very close to human understanding and can identify situations, questions, opinions, suggestions, intentions and complaints in customer feedback.
The data collected by viavoo is intended to provide marketing and customer relationship insights that help to use the customer’s own voice to improve customer experience, differentiation, loyalty and retention.

 

Sector 
Industry
Entry Date 
2011
Business 
Mezzanine Buyout & Growth Capital
Sales 
€70 million in 2014

Groupe CMR

Production and marketing of marine electrical equipment

Headquartered in Marseille, CMR Group designs, manufactures and markets sensors, switchboards, engine monitoring systems and electrical cabinets for the marine, power and oil & gas markets. Mezzanis 2 invested as part of the buyout of the CMR Group by LBO France.

Sector 
Retail & Distribution
Entry Date 
2011
Business 
Mezzanine Buyout & Growth Capital
Sales 
€145 million in 2014

Daltys

Hot and cold drink, sweet and sandwich vending machines for businesses

Daltys markets and operates hot and cold drink, sweet and sandwich vending machines for businesses, the healthcare and the hotel & catering sectors. Daltys’ installed base of 55,000 vending machines makes it the leading operator in France, with over 18,000 customers. The company also develops coffee-shop and multi-service concepts for public spaces.
In June 2011, Mezzanis arranged the mezzanine debt put in place in connection with the buyout of Daltys by its CEO Christophe Brancato plus 21 Centrale Partners and finadvance.

 

Sector 
SaaS / Cloud
Entry Date 
2011
Business 
Venture Capital

Trusted Shops

European leader in subscription-based certification of online retailers

Founded in 1999 and headquartered in Germany, the company audits online stores applying a set of over 100 criteria, such as solvency, price transparency, customer service and personal data protection. After a successful audit, Trusted Shops issues the Trust Badge seal of approval and provides the option of a guarantee for shoppers. Today, more than 20,000 ecommerce sites across Europe display the seal of approval and over 10 million purchases have been protected by the money-back guarantee.

Sector 
Medical devices
Entry Date 
2011
Business 
Venture Capital

Cellnovo

The leading pioneer in mobile diabetes management systems

Cellnovo, a company headquartered in London, provides a novel mobile system for managing type I diabetes. The Cellnovo system combines the benefits of a high-accuracy insulin patch pump, integrated activity monitor and a touchscreen, cellular enabled wireless handset with integrated blood glucose meter. The proprietary software is extremely easy to use and provides automatic connectivity to the cloud for real-time monitoring. The online data management system enables healthcare professionals to view clinical data in real time. This makes it a unique system enabling diabetics to lead a normal active life while keeping a close eye on their glycaemia, insulin use, activity and food intake.

Sector 
Infrastructure
Entry Date 
2010
Business 
Renewable Energy

Eole Infrastructure

46 MW portfolio of wind farms in France

Pages

NewsRoom
Press release
24 April 2017
Omnes Capital took part in a €4 million fundraising round of portuguese startup 360imprimir
Omnes Capital took part in a €4 million fundraising round of portuguese startup 360imprimir
Publication
Omnes Capital Newsletter n°31: Green building news H1 2017
Press release
20 April 2017
Omnes Capital announces a solid year in 2016 and sets out its development priorities for 2017
Omnes Capital announces a solid year in 2016 and sets out its development priorities for 2017
Press release
30 March 2017
Omnes Capital, with the support of co-investors Capital Transmission and Bpifrance, acquires a stake in Groupe RGF as part of a management buy-in (MBI)
Omnes Capital, with the support of co-investors Capital Transmission and Bpifrance, acquires a stake in Groupe RGF as part of a management buy-in (MBI)
Press release
17 March 2017
MultiX raises €3.5 million with Omnes Capital and its long-standing investors to launch production and secure its international business expansion
MultiX raises €3.5 million with Omnes Capital and its long-standing investors to launch production and secure its international business expansion
Publication
Omnes Capital Newsletter n°31: renewable energy news H1 2017

Pages